BAYER ADVIA CENTAUR CA 19-9 ASSAY

System, Test, Carbohydrate Antigen (ca19-9), For Monitoring And Management Of Pancreatic Cancer

BAYER HEALTHCARE, LLC

The following data is part of a premarket notification filed by Bayer Healthcare, Llc with the FDA for Bayer Advia Centaur Ca 19-9 Assay.

Pre-market Notification Details

Device IDK031393
510k NumberK031393
Device Name:BAYER ADVIA CENTAUR CA 19-9 ASSAY
ClassificationSystem, Test, Carbohydrate Antigen (ca19-9), For Monitoring And Management Of Pancreatic Cancer
Applicant BAYER HEALTHCARE, LLC 511 BENEDICT AVE. Tarrytown,  NY  10591
ContactKenneth T Edds
CorrespondentKenneth T Edds
BAYER HEALTHCARE, LLC 511 BENEDICT AVE. Tarrytown,  NY  10591
Product CodeNIG  
CFR Regulation Number866.6010 [🔎]
DecisionSubstantially Equivalent (SESE)
TypeTraditional
3rd Party ReviewedNo
Combination ProductNo
Date Received2003-05-02
Decision Date2003-06-24
Summary:summary

NIH GUDID Devices

Device IdentifiersubmissionNumberSupplement
00630414598192 K031393 000
00630414447926 K031393 000
00630414574028 K031393 000
00630414574257 K031393 000
00630414577128 K031393 000
00630414577135 K031393 000
00630414598161 K031393 000
00630414598178 K031393 000
00630414598185 K031393 000
00630414293516 K031393 000

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.